FormsNet3 - Blank Form


 

 
Sequence Number:    

 

 
Date Received: __ __ __ __ - __ __- __ __  

 

 
CIBMTR Center Number:    

 

 
CIBMTR Recipient ID:    

 

 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

HCT Type: (check all that apply) 

 

 

gfedcb
Autologous

 

 

gfedcb
Allogeneic, unrelated

 

 

gfedcb
Allogeneic, related

Product type: (check all that apply) 

 

 

gfedcb
Bone marrow

 

 

gfedcb
PBSC

 

 

gfedcb
Single cord blood unit

 

 

gfedcb
Multiple cord blood units

 

 

gfedcb
Other product

 

 
Specify:    

 

 
Is this the report of a second or subsequent transplant for the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 

 
1  What was the date of diagnosis? __ __ __ __ - __ __- __ __  

Specify whether the recipient expressed the following clinical features at diagnosis:  

 

 
2  Adenopathy

    
 nmlkji

yes  
 nmlkji

no  

 

 
3  Hepatomegaly

    (liver edge palpable > 3 cm below right costal margin) 

 nmlkji
yes  

 nmlkji
no  

 

 
4  Neurofibromatosis

    
 nmlkji

yes  
 nmlkji

no  

 

 
5  Skin involvement

    
 nmlkji

yes  
 nmlkji

no  

 

 
6  Splenomegaly

    (spleen palpable > 3 cm below left coastal margin) 

 nmlkji
yes  

 nmlkji
no  

  Key Fields 

Subsequent Transplant 

  Clinical Features at Diagnosis Questions: 1 - 6

  Laboratory Studies at Diagnosis Questions: 7 - 48

Form 2015 R3.0: Juvenile Myelomoncytic Leukemia (JMML/JCML) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2015 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 1 / 7



Report findings prior to any first treatment of the primary disease for which the HCT is being performed. 

 

 
7  WBC

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
8     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
9  Hemoglobin

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
10     

 

 

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 

 
11  Was RBC transfused < 30 days before date of test?

    
 nmlkji

yes  
 nmlkji

no  

 

 
12  Platelets

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
13     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
14  Were platelets transfused < 7 days before date of test?

    
 nmlkji

yes  
 nmlkji

no  

 

 
15  Monocytes

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
16     % 

 

 
17  Absolute monocyte count

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
18     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
19  Blasts in blood

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
20     % 

 

 
21  LDH

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
22     

 

 

 nmlkji
U/L  

 nmlkji
µkat/L  

 

 
23  Upper limit of normal for LDH:    

 

 

 nmlkji
U/L  

 nmlkji
µkat/L  

 

 
24  Fetal hemoglobin

    (HbF)  

 nmlkji
Known  

 nmlkji
Unknown  

Form 2015 R3.0: Juvenile Myelomoncytic Leukemia (JMML/JCML) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2015 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 2 / 7



 

 
25     % 

 

 
26  Was testing performed for hypersensitivity to GM-CSF?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify test results: 

 

 
27  Specify result

    
 nmlkji

Positive  
 nmlkji

Negative  

 

 
28  Was a bone marrow examination performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
29  Blasts in bone marrow:    % 

 

 
30  Monocytes in bone marrow:    % 

 

 
31  Was documentation submitted to the CIBMTR?

    (e.g. examination report)  

 nmlkji
yes  

 nmlkji
no  

 

 
32  Were cytogenetics tested (conventional or FISH)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
33  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

Specify cytogentic abnormalities identified at diagnosis:  

Monosomy 

 

 
34  -7

    
 nmlkji

yes  
 nmlkji

no  

Trisomy 

 

 
35  +8

    
 nmlkji

yes  
 nmlkji

no  

 

 
36  +21

    
 nmlkji

yes  
 nmlkji

no  

Translocation 

 

 
37  t(2;8)

    
 nmlkji

yes  
 nmlkji

no  

 

 
38  t(9;22)

    
 nmlkji

yes  
 nmlkji

no  

Other 

 

 
39  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 

 
40  Specify other abnormality:    

Form 2015 R3.0: Juvenile Myelomoncytic Leukemia (JMML/JCML) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2015 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 3 / 7



 

 
41  Was documentation submitted to the CIBMTR?

    (e.g. cytogentic or FISH report)  

 nmlkji
yes  

 nmlkji
no  

 

 
42  Were tests for molecular markers performed (e.g. PCR)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
43  BCR / ABL

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
44  CBL

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
45  KRAS

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
46  NRAS

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
47  PTNP11

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
48  Was documentation submitted to the CIBMTR?

    
 nmlkji

yes  
 nmlkji

no  

 

 
49  Was therapy given?

    
 nmlkji

yes  
 nmlkji

no  

Specify therapy given:  

 

 
50  6-Mercaptopurine

    
 nmlkji

yes  
 nmlkji

no  

 

 
51  13-cis-retinoic acid (RA)

    
 nmlkji

yes  
 nmlkji

no  

 

 
52  Cytarabine (Ara-C)

    
 nmlkji

yes  
 nmlkji

no  

 

 
53  Fludarabine

    
 nmlkji

yes  
 nmlkji

no  

 

 
54  Ruxolitinib (Jakafi)

    
 nmlkji

yes  
 nmlkji

no  

 

 
55  Did the recipient have a splenectomy?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
56  Did the recipient receive splenic irradiation?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Pre-HCT Therapy Questions: 49 - 62

Form 2015 R3.0: Juvenile Myelomoncytic Leukemia (JMML/JCML) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2015 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 4 / 7



 

 
57  Other therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
58  Specify other therapy:    

 

 
59  Was a complete remission achieved?

    
 nmlkji

yes  
 nmlkji

no  

 

 
60  Date of complete remission: __ __ __ __ - __ __- __ __  

 

 
61  Was there disease relapse?

    
 nmlkji

yes  
 nmlkji

no  

 

 
62  Date of relapse: __ __ __ __ - __ __- __ __  

 

 
63  Did transformation to acute myelogenous leukemia (AML) occur?

    
 nmlkji

yes  Also complete CIBMTR Form 2010-AML 

 nmlkji
no  

 

 
64  Date of transformation: __ __ __ __ - __ __- __ __  

 

 
65  Fetal hemoglobin

    (HbF)  

 nmlkji
Known  

 nmlkji
Unknown  

 

 
66     % 

 

 
67  Monocytes

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
68     % 

 

 
69  Absolute monocyte count

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
70     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
71  Blasts in blood

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
72     % 

 

 
73  Were cytogenetics tested (conventional or FISH)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
74  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

  Transformation Questions: 63 - 64

  Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen (Conditioning) Questions: 65 - 91

Form 2015 R3.0: Juvenile Myelomoncytic Leukemia (JMML/JCML) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2015 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 5 / 7



Specify cytogenetic abnormalities identified at last evaluation prior to the start of the preparative regimen: 

Monosomy 

 

 
75  -7

    
 nmlkji

yes  
 nmlkji

no  

Trisomy 

 

 
76  +8

    
 nmlkji

yes  
 nmlkji

no  

 

 
77  +21

    
 nmlkji

yes  
 nmlkji

no  

Translocation 

 

 
78  t(2;8)

    
 nmlkji

yes  
 nmlkji

no  

 

 
79  t(9;22)

    
 nmlkji

yes  
 nmlkji

no  

Other 

 

 
80  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 

 
81  Specify other abnormality:    

 

 
82  Were tests for molecular markers performed (e.g. PCR)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
83  BCR / ABL

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
84  CBL

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
85  KRAS

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
86  NRAS

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
87  PTNP11

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
88  Was a bone marrow examination performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
89  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
90  Blasts in bone marrow:    % 

 

 
91  Monocytes in bone marrow:    % 

  Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen (Conditioning) Questions: 92 - 93

Form 2015 R3.0: Juvenile Myelomoncytic Leukemia (JMML/JCML) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2015 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 6 / 7



 

 
92  What was the disease status?

    (based on international JMML diagnostic criteria)  

 nmlkji
Complete remission (CR)  - normalization of WBC and organomegaly  

 nmlkji
Partial remission (PR)  - ≥ 50% reduction in WBC and/or organomegaly  

 nmlkji
Marginal 

response  

- between 25% and 50% reduction in WBC and organomegaly ~ or ~ partial response in WBC but no change in organomegaly ~ or ~ partial response 
in organomegaly but no change in WBC  

 nmlkji
Stable disease (SD)  - ≤ 25% reduction in WBC and/or organomegaly  

 nmlkji
Progressive disease (PD)  - increase in WBC and/or organomegaly  

 nmlkji
Relapse  -  ≥ 20% blasts in the bone marrow  

 nmlkji
Not assessed  

 

 
93  Date assessed: __ __ __ __ - __ __- __ __  

 

 
First Name:    

 

 
Last Name:    

 

 
E-mail address:    

 

 
Date: __ __ __ __ - __ __- __ __  

Form 2015 R3.0: Juvenile Myelomoncytic Leukemia (JMML/JCML) Pre-HCT Data  
Center:  CRID: 

           CIBMTR Form 2015 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 7 / 7